Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Autoimmune Diseases × telitacicept × Clear all

Phase

Status

Not yet recruiting 2 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1 Muscle Weakness 1 Autoimmune Diseases 1

Interventions

Data Collection 3 telitacicept 1 human papillomavirus vaccine, L1 type 16, 18 1 Vitamin D 1 Plasma Exchange 1 Immune Checkpoint Inhibitors 1 Fish Oils 1 Fatty Acids, Omega-3 1 Eicosapentaenoic Acid 1 Docosahexaenoic Acids 1 Cholecalciferol 1 CT-P13 1 Ashwagandha 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05737160 2025-05-23

Study of Telitacicept in Generalized Myasthenia Gravis

RemeGen Co., Ltd.

Phase 3 Completed

Autoimmune Diseases, Myasthenia Gravis, Muscle Weakness

Data powered by HemOnc (CC BY 4.0) Colophon ⚡